Skip to content

Idiopathic Intracranial Hypertension

IIH (pseudotumour cerebri) — a Sydney guide for patients, families and referring GPs

Idiopathic intracranial hypertension is raised pressure of the fluid around the brain with no obvious cause. It causes headache and can affect eyesight.

Dr. Hugh Stephen Winters
Reviewed by
Dr. Hugh Stephen Winters
Stroke and Interventional Neurologist · MBChB (Auckland) · FRACP (Neurology) · CCINR (Neurology)
Last reviewed 13 September 2026

Most people with IIH keep their vision. If your GP has just mentioned IIH, take a breath — with monitored treatment, the great majority of patients protect their sight and bring their headaches under control. The emergency notice below is for people with rapidly worsening symptoms right now.

The emergency notice below applies only if you currently have rapidly worsening symptoms. If your symptoms are stable, you can scroll past it.

Book an IIH consultation →

GP? Jump to referrer information →

At a glance
  • Most people with IIH retain functional vision with structured monitoring. Permanent visual impairment is concentrated in untreated, late- presenting, and fulminant cases — structured monitoring with regular eye examinations, optic-disc imaging, and visual-field testing is the single biggest protective factor.
  • IIH affects approximately 12–20 women per 100,000 aged 20–44 with a BMI over 30 (Markey, Mollan, Sinclair, Lancet Neurology 2016). Female-to-male ratio is about 8–10:1.
  • First-line medical treatment is acetazolamide, supported by the NORDIC Idiopathic Intracranial Hypertension Treatment Trial (Wall et al., JAMA 2014).
  • Transverse sinus stenting is performed by our three interventional neurologists — Dr Hugh Stephen Winters, Dr Timothy Ang, and Dr Emma Harrison — at affiliated Sydney hospitals when imaging and venographic pressure measurements identify a treatable venous sinus stenosis.
  • IIH most commonly affects women aged 20–40. Pregnancy, contraception and weight-management decisions are part of the planning conversation — not afterthoughts.
Directory

You’ve just been told you might have IIH — what now?

Today

  • Breathe. Most people with IIH protect their vision and get their symptoms under control with the right plan.
  • If you have rapidly worsening vision, new double vision, or the worst headache of your life — this is an emergency. Go to ED or call 000.
  • Ask your GP or optometrist for copies of any fundus photos, OCT scans, or visual-field reports. These are the most useful single pieces of information for our first appointment.

This week

  • Ask your GP for a referral to a neurologist with IIH experience. Mention papilloedema (if present) and any vision changes — these trigger urgent triage at CURA.
  • If you’ve had a recent MRI, check that MR venography (MRV) was included. If it wasn’t, the scan may need to be repeated — MRV looks at the brain’s drainage veins and is essential for IIH. If you’re unsure, don’t worry: we can resolve this at the consultation and decide together whether another MRI/MRV is needed.
  • Make a list of all your medications including the contraceptive pill, any acne treatments, tetracycline antibiotics (doxycycline, minocycline), and high-dose vitamin A — some can trigger or worsen IIH.

This month

  • Book the consultation. Bring your GP referral, any imaging you have (on USB or via secure link) with the radiology reports, your medication list, and your Medicare card. Most of our neurologists can access scans directly from the popular radiology providers, so don’t delay booking if you can’t get hold of them.
  • You’ll leave with a written plan: confirmation of diagnosis (or what’s still needed to confirm it), medication started or adjusted, eye-monitoring cadence, and the trigger points that would move us toward stenting or surgery.

Symptomatic IIH with vision change is triaged urgently. Stable incidental presentations are seen routinely.

The team

Your Sydney IIH team

I.

What IIH is

Idiopathic intracranial hypertension (IIH) — sometimes called pseudotumour cerebri — is a condition in which the pressure of the cerebrospinal fluid around the brain is elevated without an obvious cause.

The brain and spinal cord float in a thin layer of clear fluid, the . That fluid is constantly produced, circulated, and reabsorbed. In IIH, the balance is disturbed — pressure rises — and the consequences fall most heavily on the optic nerves, which are particularly vulnerable to swelling at their entry into the eye (called papilloedema).

The word idiopathic just means “we can’t identify a single triggering cause”. It does not mean untreatable. Modern care focuses on three things, in this order:

  • Protecting vision — the most serious potential consequence.
  • Controlling the pressure — with medication, and where appropriate, procedures.
  • Managing the headache — which often has multiple coexisting drivers (see Section V).

A note on terminology: the older name pseudotumour cerebri is still used. The modern (2013) distinguish primary (idiopathic) intracranial hypertension from secondary intracranial hypertension — the latter is driven by an identifiable cause (e.g. a venous sinus thrombosis, certain medications, or an endocrine disorder) and is managed differently.

II.

Symptoms and warning signs

Headache — the most common symptom

Headache affects roughly nine in ten people with IIH and is often the symptom that finally drives the diagnosis. The classic raised-pressure pattern is:

  • Worse first thing in the morning or after lying down for a while
  • Worse with coughing, sneezing, or straining (Valsalva)
  • Often felt as pressure behind the eyes or across the head
  • Eased, at least partially, when the pressure is brought down

But not every headache in someone with IIH is a pressure headache — coexisting migraine, occipital and cervicogenic headaches are common, and matter for treatment (see Section V).

Vision symptoms

Around seven in ten patients describe one or more of:

  • — brief greyouts or blackouts lasting seconds, often when bending or standing up. A warning sign worth flagging on referral.
  • Blurred or double vision
  • Peripheral vision loss — usually only detected on formal because patients rarely notice it themselves until it is advanced
  • Flashing lights or sparkles in the visual field

Pulsatile tinnitus

Many patients describe a whooshing or pulsing sound in one or both ears that matches their heartbeat. It is one of the more characteristic IIH symptoms and is often the clinical clue that prompts MR venography.

Less common but worth noting

  • Nausea and vomiting
  • Dizziness or balance problems
  • Neck and shoulder pain
  • Memory and concentration problems
  • Persistent fatigue
III.

Causes and risk factors

IIH is, by definition, idiopathic — we cannot point to a single trigger. But the population of people who develop it has consistent features.

Demographic risk

  • Female sex and reproductive-age years. IIH is roughly 8–10 times more common in women than in men, and most cases present between 20 and 40 years of age.
  • Body weight. Approximately 90% of women diagnosed with IIH are above a healthy BMI (BMI ≥25), with the majority in the obese range. The relationship is real and important, but weight is one factor among several — not a moral category, and not the whole story.
  • Recent weight gain can precipitate IIH even in people not classified as obese.

IIH in men

Men account for around 5–10% of IIH cases. Most men with IIH are also above a healthy BMI, but compared with women the condition shows a stronger association with obstructive sleep apnoea and low testosterone, and tends to present with more severe visual loss at diagnosis. For both reasons, a sleep study and morning testosterone are part of the standard CURA workup in any male IIH patient, and we monitor vision more aggressively in the early months.

Medications and substances

Several medications can trigger or worsen IIH. Bring a complete list to your consultation. Common contributors:

  • Tetracycline antibiotics — particularly doxycycline and minocycline (often prescribed for acne)
  • High-dose vitamin A and retinoid acne medications (isotretinoin)
  • Some corticosteroids, particularly on withdrawal
  • Lithium (uncommonly)

Coexisting medical conditions

  • Obstructive sleep apnoea
  • Polycystic ovary syndrome (PCOS)
  • Chronic kidney disease
  • Some autoimmune conditions, including lupus
  • Iron deficiency anaemia (in some series)
IV.

How IIH is diagnosed

IIH is diagnosed using the modified Friedman criteria (Friedman, Liu, Digre, Neurology 2013). All five elements must be present.

The five Friedman elements
  • 1. Papilloedema — swelling of the optic nerve head, on fundoscopy or OCT.
  • 2. Normal neurological examination apart from cranial-nerve findings (most often a sixth-nerve palsy).
  • 3. Brain MRI with MR venography showing no tumour, hydrocephalus, structural lesion, or venous sinus thrombosis.
  • 4. Normal CSF composition on lumbar puncture analysis.
  • 5. Elevated lumbar-puncture opening pressure — ≥25 cmH₂O in adults regardless of BMI, with a recognised 20–25 cmH₂O grey zone in which the diagnosis can still be made if all the other criteria are met. The measurement is taken with you lying on your side and relaxed — positioning matters for the reading to be valid.

In practice, your workup is built from a neurology consult, eye-specialist tests (OCT and visual fields), an MRI with MR venography, and a lumbar puncture — usually arranged as separate bookings, either before or shortly after the consult depending on what’s already been done.

Read the full workup detail (history, MRI/MRV, lumbar puncture, eye tests) ↓

What the workup looks like in practice

History and examination. Your neurologist takes a detailed history (headache pattern, vision changes, medications, obstetric history), examines the cranial nerves and the back of each eye, and reviews any previous optometry or ophthalmology records you bring.

Eye-specialist input. Detailed eye examination is central. We coordinate with optometry and neuro-ophthalmology colleagues for and visual-field testing — together these are the most sensitive tools for catching early visual change.

MRI brain with MR venography. An MRI is required to exclude a tumour, hydrocephalus, or other structural cause, and to look for the changes around the optic nerves and pituitary that often accompany IIH. The MR venography sequence is essential — it examines the brain’s draining veins and identifies both the venous sinus narrowing commonly seen in IIH and the venous sinus thrombosis that excludes it. If your earlier MRI was done for headache and didn’t include MRV, the scan often needs to be repeated with the right protocol.

Lumbar puncture (LP). The LP confirms the diagnosis by measuring the opening pressure of the spinal fluid and excluding infection or other abnormalities. A thin needle is placed in the lower back under local anaesthetic with you lying on your side; the LP itself takes about 10 minutes, and the appointment overall around 1–2 hours including positioning, recovery and observation. A well-recognised side effect is post-LP headache, which is usually self-limiting.

Visual field testing maps each eye’s field and picks up the characteristic blind-spot enlargement and other patterns of pressure-related optic-nerve change. Any abnormality here is a trigger to escalate monitoring or treatment urgently.

V.

Understanding headaches in IIH

Headache is the symptom that most often disrupts daily life with IIH — and it is almost never just one kind of headache. Pressure-related headache is the starting point, but coexisting patterns matter for treatment.

Pressure-related headaches

Caused directly by the raised intracranial pressure. Worse on lying down or bending over, eased by standing, often felt as pressure behind the eyes. These tend to improve when the pressure comes down — with acetazolamide, weight loss, or stenting.

Coexisting headache types

  • Migraine — can be triggered or worsened by IIH and may persist even after pressure normalises. Modern preventives include the CGRP-pathway therapies — the anti-CGRP-receptor and anti-CGRP-ligand monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) and the oral gepants (atogepant, rimegepant). Triptans and gepants are used for acute attacks where not contraindicated. PBS authority criteria apply to several of these and are reviewed at consultation.
  • Occipital and cervicogenic — arising from tension and altered posture in the muscles at the base of the skull and neck. Greater occipital nerve blocks can give rapid relief.
  • Medication-overuse headache — analgesics taken on more than 10–15 days a month can themselves drive a chronic daily headache pattern. This is one of the things we look for at the first consult.

Why this matters

Reducing intracranial pressure helps many of these headaches, but rarely resolves all of them on its own. Effective IIH headache management almost always involves layered treatment — pressure control plus targeted therapy for the headache phenotype that remains. This is one of the reasons IIH benefits from a headache-specialist neurologist and an interventional neurologist within the same practice — exactly the structure at CURA.

VI.

Treatment — medical, endovascular, and surgical

Treatment has three goals, in priority order: protect vision, control pressure, and relieve headache. The right combination depends on how threatening the disease is to the eyes, how disabling the headache is, the presence or absence of a venous sinus stenosis on imaging, and personal factors like pregnancy plans.

Read full treatment detail ↓

Lifestyle and weight

For overweight and obese patients, sustained 5–10% body-weight loss reduces intracranial pressure and improves symptoms in most cases. The IIH:WT trial (Mollan et al., JAMA Neurology 2021) showed bariatric surgery was more effective than community weight management for sustained pressure reduction in patients with severe obesity.

A 2023 randomised trial of exenatide in IIH (Mitchell, Sinclair et al., Brain 2023) reported a reduction in intracranial pressure that appeared at least partly independent of weight loss. The newer weight-loss agents — semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GIP/GLP-1 agonist) — are subsequently thought to be of some benefit in IIH on a similar basis, although direct trial-level evidence in IIH is not yet established for these agents. In current Australian practice they are used as part of weight-directed therapy. Salt and fluid moderation, and dietetic support, remain part of the plan when relevant.

Medications

  • Acetazolamide is first-line. It reduces CSF production. The NORDIC IIH Treatment Trial established the modern evidence base. Acetazolamide is used in IIH on a private script in Australia; cost varies by pharmacy and is reviewed at consultation. Dosing is titrated to tolerance — common dose-limiting side effects are paraesthesiae (tingling in the fingers and toes), dysgeusia (the metallic taste, often described as flat fizzy drinks), fatigue, and, less commonly, kidney stones.
  • Topiramate is a second-line option, with mild carbonic-anhydrase activity and the side benefit of weight loss. It is teratogenic: first-trimester exposure carries an increased risk of fetal harm, and use in anyone who could become pregnant requires reliable contraception — the specific options and counselling are discussed at consultation with your prescriber. A particularly important caveat given that IIH predominantly affects women aged 20–40.
  • Furosemide is occasionally added to acetazolamide where the response is partial. It is not used as a substitute.

Procedures — in priority order of how often we use them

Therapeutic lumbar puncture. Repeated LPs can give temporary relief while medical therapy takes effect, and occasionally to bridge to a definitive procedure. Used sparingly because of the discomfort and modest durability.

Transverse sinus stenting — an endovascular procedure performed by our three interventional neurologists (Dr Hugh Stephen Winters, Dr Timothy Ang, Dr Emma Harrison) at affiliated Sydney hospitals. See the next section for detail.

Optic nerve sheath fenestration (ONSF). A microsurgical procedure performed by neuro-ophthalmology colleagues that creates small openings in the sheath around the optic nerve to relieve local pressure. ONSF is generally used as a surgical adjunct alongside other treatments when vision is acutely threatened — not as an isolated solution — and is less effective for headache.

CSF shunting. A neurosurgical procedure that places a tube to drain excess CSF from the brain to the abdomen (ventriculoperitoneal) or from the lower back (lumboperitoneal). Generally reserved for severe disease that has not responded to medication or stenting. Shunts have the highest revision and complication rates of the IIH procedures, and most patients require one or more revision surgeries over time.

How we choose between them

The choice depends on whether vision is acutely threatened, whether headache is the dominant problem, whether MRV shows a treatable venous sinus stenosis, and the patient’s anatomy and preferences. ONSF is added as a vision-protection adjunct; stenting addresses both pressure and headache when there is a venous stenosis; shunting is the fallback when neither is appropriate.

VII.

Transverse sinus stenting

Transverse sinus stenting is performed by Dr Hugh Stephen Winters, Dr Timothy Ang, and Dr Emma Harrison at affiliated Sydney hospitals — the consult, decision-making, and follow-up sit with the practice; the procedure itself is inpatient.

Read stenting detail (candidacy, procedure, outcomes) ↓

A meaningful proportion of patients with IIH have narrowing (stenosis) of one or both transverse venous sinuses on MR venography. In selected patients, this stenosis contributes mechanically to the raised pressure: blood backs up, drainage falls, intracranial pressure rises. Restoring venous outflow with a stent can reverse the cycle.

Who is a candidate

  • MR venography evidence of significant transverse or sigmoid sinus stenosis — typically bilateral, sometimes dominant-side unilateral.
  • Persistent or progressive symptoms despite medical therapy, or intolerance of medication.
  • A pressure gradient across the stenosis confirmed at catheter venography — the procedure that also places the stent. The pressure gradient, not the imaging appearance alone, is the procedural threshold; some MRV-apparent stenoses are non-physiological and do not warrant intervention.

What the procedure involves

Catheter venography and stenting is performed under general anaesthesia at an affiliated Sydney hospital. A catheter is passed from a small puncture in the groin to the brain’s draining veins. Pressures are measured on either side of the stenosis. If a treatable gradient is confirmed, a self-expanding stent is deployed across the narrowing. Hospital stay is typically 1–2 nights.

Patients are placed on dual antiplatelet therapy (aspirin plus clopidogrel or ticagrelor) commencing before the procedure and continuing for several months afterwards, with a long-term aspirin tail. Where appropriate, pre-procedure platelet-function testing is used to confirm responsiveness to clopidogrel and switch the regimen if indicated.

Outcomes and risks

In appropriately selected patients, around 75–85% see meaningful headache improvement and papilloedema resolution in published systematic reviews (e.g. Saber et al., 2018; Nicholson et al., 2019). Serious peri-procedural complications (intracranial bleeding, stent thrombosis) occur in roughly 1–2% of cases in the same series; minor complications such as a temporary headache on the side of the stent are more common. The long-term effects of having a permanent intracranial stent — particularly in young patients — are still being studied, and this is part of the consultation conversation.

VIII.

IIH in pregnancy and contraception

IIH most commonly affects women aged 20–40. Pregnancy planning, contraception, and the risk profile of the medications used in IIH all need to be on the table from the first consultation — not when a positive pregnancy test arrives.

Read full pregnancy and contraception detail ↓

Pregnancy

Pregnancy in IIH is co-managed with obstetrics and (where needed) obstetric medicine. Key principles:

  • Acetazolamide in pregnancy is increasingly individualised. Earlier guidance favoured avoiding it in the first trimester, and that remains the conservative default; current obstetric-medicine practice supports continued use through pregnancy where vision is at stake, with informed consent and joint maternal-fetal medicine review. If acetazolamide cannot be used and pressure is threatening vision, the threshold to consider stenting may be lower.
  • Topiramate is teratogenic — first-trimester exposure carries an increased risk of fetal harm. Use in anyone who could become pregnant requires reliable contraception and ongoing review with your prescriber. If you are on topiramate and pregnancy is a possibility, raise this at consultation immediately so we can sequence a switch under contraceptive cover.
  • OCT and visual-field monitoring are safe in pregnancy and become more important.
  • IIH does not in itself mandate caesarean delivery. Mode of delivery is decided jointly with obstetrics; epidural anaesthesia is generally not contraindicated.
  • Active weight-loss programs are deferred until after delivery and postpartum recovery.

Contraception

The combined oral contraceptive pill has historically been listed as a possible association with IIH onset, but a causal role is not established and modern reviews do not treat it as a meaningful trigger. The contraceptive question that does matter is topiramate: where topiramate is used, reliable contraception is required and the specific options are reviewed with your prescriber.

IX.

Long-term monitoring

IIH is a chronic condition rather than a one-time illness, and monitoring intensity is matched to disease activity, not the calendar.

In active disease — close monitoring

  • For active papilloedema or any visual-field abnormality: weekly to fortnightly review until stable, then monthly, with frequency stepped down only as OCT and perimetry confirm sustained improvement.
  • Fulminant or rapidly worsening cases may require daily review until stabilised.

In stable disease — surveillance

  • Eye examinations every 6–12 months once papilloedema has resolved and visual fields are stable.
  • Neurology review every 6–12 months.
  • Repeat MRI/MRV if symptoms change, the headache pattern shifts, or a new finding appears.

What OCT shows

OCT gives objective, repeatable measurements of the optic disc and surrounding retina. In IIH, it is used to quantify the swelling of the optic nerve head over time and to detect any thinning of the nerve’s structural layers — an early signal that pressure is doing damage and treatment needs to escalate. Your eye specialist will interpret the trend on each scan rather than any single number.

X.

At your consultation

A first IIH consultation usually takes 45–60 minutes. The consultation itself is the first appointment; imaging, eye-specialist tests and lumbar puncture are organised as separate bookings — either ahead of the consult (so we can review the results with you) or shortly after, depending on what’s needed.

Bring

  • Your GP referral letter
  • Any imaging you have, on USB or via secure link — CTs, MRIs (especially anything with MR venography), plus the radiology reports. Most of our neurologists can access scans at most popular radiology providers, so this is helpful rather than essential.
  • Any optometry or ophthalmology records: fundus photos, OCT scans, visual field reports
  • A current medication list including the contraceptive pill, any acne treatments, tetracycline antibiotics, vitamin A supplements, and any over-the-counter medicines
  • Recent blood pressure readings if you have them
  • Medicare card and any private health insurance details
  • A family member or friend — a second pair of ears is invaluable when there’s a lot of new information

What the consult typically covers

Specifics depend on your presentation and what’s already been done. Where appropriate, we’ll:

  • Review your history, examine you, and review your imaging
  • Arrange or coordinate any further tests still needed — as separate bookings. OCT and visual-field testing are performed by our ophthalmology and optometry partners; MRI/MR venography is performed at imaging providers; lumbar puncture is arranged through our usual pathway. We coordinate the referrals and consolidate the results.
  • Confirm or rule out the diagnosis against the modified Friedman criteria
  • Start or adjust medication, set the eye-monitoring cadence, and discuss the trigger points that would move us toward stenting or surgery
  • Send a written letter to your GP with a clear shared-care plan

Fees and wait time

Consultation fees and out-of-pocket gaps depend on consultation type and your Medicare and private-health eligibility. Lumbar puncture, MRI/MR venography, OCT, and visual-field testing are Medicare-rebatable when ordered for a clinical indication. Wait times depend on triage urgency — symptomatic IIH with vision change is triaged urgently. See our current fees → or call reception / use the online booking page.

Q&A

Frequently asked questions

Who treats IIH in Sydney?

At CURA Medical Specialists in Drummoyne, Sydney, idiopathic intracranial hypertension is managed by a four-neurologist team. Three of the four are stroke and interventional neurologists who perform transverse sinus stenting personally: Dr Hugh Stephen Winters (FRACP, CCINR), Dr Timothy Ang (FRACP, CCINR), and Dr Emma Harrison (FRACP, CCINR). Dr Usman Ashraf (Headache Specialist Neurologist, FRACP) leads the medical and headache-management side of IIH care and refers in to the interventional team where stenting is indicated. Having headache subspecialty care and an interventional team that performs stenting personally — at affiliated Sydney hospitals — under the same practice is uncommon in Australia.

Will I lose my vision from IIH?

Most people with IIH retain functional vision with structured monitoring. Permanent visual impairment is concentrated in patients with severe papilloedema, fulminant onset, or treatment that started late — historically reported around 10% in older series, with better outcomes in modern monitored cohorts. The single most important protective factor is structured monitoring with regular eye examinations, optic-disc imaging, and visual-field testing, with rapid escalation if findings move in the wrong direction. The brief seconds-long visual greyouts that many patients describe (transient visual obscurations) are a warning sign for monitoring — not the same thing as permanent blindness.

How is IIH diagnosed?

IIH is diagnosed using the modified Friedman criteria (Friedman et al., Neurology 2013). Five elements are required: papilloedema on fundoscopy or OCT; a normal neurological examination apart from cranial-nerve findings; a brain MRI with MR venography that excludes a tumour, hydrocephalus, or venous sinus thrombosis; normal cerebrospinal-fluid composition; and an elevated lumbar-puncture opening pressure (≥25 cmH₂O in adults regardless of BMI, with a 20–25 cmH₂O grey zone in which the diagnosis can still be made if all other criteria are met; >28 cmH₂O in children, or >25 cmH₂O if the child is non-sedated and non-obese). All five must be present.

Does CURA do transverse sinus stenting?

Transverse sinus stenting is a minimally invasive endovascular procedure in which a self-expanding stent is placed across a stenosis (narrowing) in one or both transverse venous sinuses, restoring venous outflow from the brain and lowering intracranial pressure. It is typically considered when catheter venography demonstrates a trans-stenotic pressure gradient across the stenosis and the patient has either failed or cannot tolerate medical therapy. The procedure is performed at affiliated Sydney hospitals by three of our interventional neurologists — Dr Hugh Stephen Winters, Dr Timothy Ang, and Dr Emma Harrison. Patients are not referred outside the practice for the procedure; CURA holds the consult, the decision, and the follow-up.

Can men get IIH?

Yes. IIH is roughly eight to ten times more common in women of childbearing age, but men account for around 5–10% of cases. In men IIH is more strongly associated with obstructive sleep apnoea and low testosterone than with body weight, and a sleep study is part of the standard workup at CURA in any male patient.

I am pregnant or planning pregnancy — what does that mean for my treatment?

Pregnancy in IIH is co-managed with obstetrics and obstetric medicine. Acetazolamide in pregnancy is increasingly individualised: the conservative default remains avoidance in the first trimester, and current obstetric-medicine practice supports continued use through pregnancy where vision is at stake, with informed consent and joint maternal-fetal medicine review. Topiramate is teratogenic — first-trimester exposure carries an increased risk of fetal harm, and use in anyone who could become pregnant requires reliable contraception with ongoing review by the prescriber. OCT and visual-field monitoring continue and become more important during pregnancy. IIH does not by itself mandate caesarean delivery — mode of delivery is decided jointly with obstetrics, and epidural anaesthesia is generally not contraindicated. Weight-loss strategies are deferred until after delivery. If pregnancy is on the horizon, please raise it at consultation so the plan can be sequenced safely.

How is acetazolamide used for IIH in Australia?

Acetazolamide (Diamox) is the first-line medical therapy for IIH in Australia. It is prescribed on a private script — cost varies by pharmacy and is reviewed at consultation. Dosing is individualised; common dose-limiting effects are paraesthesiae, dysgeusia (the metallic taste, often described as flat fizzy drinks), and fatigue. Renal-stone risk should be reviewed before starting.

Is IIH related to weight, and do I have to lose weight before you treat me?

Most women diagnosed with IIH are above a healthy BMI; approximately 90% are overweight or obese (BMI ≥25), with the majority in the obese range. Even modest sustained weight loss (roughly 5–10% of body weight) reduces intracranial pressure in most obese patients. But weight is one factor in a wider plan — not a precondition for treatment. We start medical therapy where it is needed, monitor vision, support sustained weight loss with dietetics and (where appropriate) GLP-1 agonists or bariatric referral, and intervene earlier with stenting or surgery if vision is threatened. Around 20–40% of patients do not fully respond to weight loss alone and need additional treatment.

How quickly will I be seen?

Symptomatic IIH presentations — particularly anyone with papilloedema, transient visual obscurations, or visual-field changes — are triaged urgently. Routine new-referral wait times depend on current clinic load. For live availability, please call our reception or use the online booking page. If your GP suspects fulminant IIH (rapidly progressive visual loss developing within four weeks of symptom onset), this is an emergency: go to the nearest emergency department.

Do I need a GP referral?

Yes — a current GP referral is required to claim the Medicare rebate on a specialist consultation. A GP referral is valid for 12 months; a referral from another specialist for 3 months.

What does the consultation cost?

Fees depend on consultation type and your Medicare and private-health eligibility. Current fees, expected Medicare rebate, and out-of-pocket gap are listed on our fees page (curaspecialists.com.au/fees). Lumbar puncture, MRI/MR venography, OCT and visual-field testing are Medicare-rebatable when ordered for a clinical indication. Acetazolamide is dispensed on a private script in Australia; cost varies by pharmacy and is reviewed at consultation.

Directory

For referring GPs

Triage at CURA

  • Same-day / ED first: sudden vision loss, fulminant IIH (rapidly progressive papilloedema or visual field loss over days), 6th-nerve palsy with reduced acuity.
  • Urgent CURA slot: papilloedema with transient visual obscurations, deteriorating visual fields, intolerable headache despite acetazolamide.
  • Routine new referral: suspected IIH with stable vision, papilloedema not yet confirmed, work-up needed (MRV, LP, OCT, HVF).

Worked example: BMI 32, postural headache, transient visual obscurations, papilloedema on fundoscopy = urgent slot; please flag on the referral.

What to include in the referral

  • BMI, fundoscopy or optometry findings, any OCT and visual-field results if available
  • Current medication list — particularly tetracyclines, isotretinoin, vitamin A, OCP, lithium, and any recent corticosteroid change
  • Recent MRI/MRV reports (and disc/secure link if available); flag if MRV was not included — we can arrange a re-protocoled scan
  • Pregnancy status, breastfeeding status, or active pregnancy planning
  • Symptomatology — especially transient visual obscurations, new double vision, pulsatile tinnitus

How to refer

Referrals are accepted via secure messaging, fax, and email. For current HealthLink EDI, fax, and email details, please contact our reception or visit the Refer a Patient page. To flag urgency on a specific referral, call our reception directly.

What we send back

A written consultation letter to the referring GP, with confirmed or provisional diagnosis against the modified Friedman criteria, imaging recommendations, medication started or adjusted, eye- monitoring cadence, and a clear plan for shared care.

XII.

Patient resources

  • IIH UK — iih.org.uk. The largest English-language IIH-specific patient charity, with up-to-date plain-English explainers, treatment guides, and a patient community.
  • Brain Foundation Australia — brainfoundation.org.au
  • Healthdirect Australia — healthdirect.gov.au (Healthdirect helpline 1800 022 222)
  • NORDIC IIHTT trial summary — Wall et al., JAMA 2014; the trial that anchors first-line acetazolamide therapy.
  • NSW Ambulance — 000 for any emergency

References cited in this guide

  • Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159–1165.
  • Wall M, McDermott MP, Kieburtz KD, et al. (NORDIC IIHTT Study Group). Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the IIH treatment trial. JAMA. 2014;311(16):1641–1651.
  • Markey KA, Mollan SP, Jensen RH, Sinclair AJ. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurology. 2016;15(1):78–91.
  • Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088–1100.
  • Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurology. 2021;78(6):678–686.

CURA Medical Specialists — idiopathic intracranial hypertension care in Drummoyne, Sydney’s Inner West. Book a consultation · For referring GPs